文献速递神经肿瘤

再程放疗在复发4级胶质瘤治疗中不断演变的作用

The evolving role for re-irradiation in the management of recurrent grade 4 glioma.
PubMed 文献 · J Neurooncol · 2017-04-06

本文综述再程放疗用于复发4级胶质瘤的演变,指出多数患者在原治疗野内局部复发,现代影像技术与精准放疗使再程放疗成为可行选择,可实现姑息获益并延长生存且毒性低,并讨论潜在靶向放射增敏剂。

要点

  • 多数4级胶质瘤患者最终在原治疗野内局部复发,需要新的局部治疗策略。
  • 现代影像技术与精准放疗技术使再程放疗成为可行选择,毒性率低。
  • 再程放疗可实现姑息获益并延长生存,本文并讨论潜在靶向放射增敏剂。

核心结论

  • 使用现代影像技术和精准放疗技术,再程放疗已被证明是可行选择,可实现姑息获益并延长生存,且毒性率低。

研究设计与样本

  • 本文为综述,回顾再程放疗作为复发4级胶质瘤治疗方式的演变,并讨论与再程放疗联用的潜在靶向放射增敏剂。

主要发现

  • 多数4级胶质瘤患者最终在原治疗野内局部复发。
  • 对毒性的担忧限制了再程放疗作为治疗选择的热情。
  • 使用现代影像技术和精准放疗技术,再程放疗已被证明可实现姑息获益并延长生存,且毒性率低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although significant gains have been realized in the management of grade 4 glioma, the majority of these patients will ultimately suffer local recurrence within the prior field of treatment. Clearly, novel local treatment strategies are required to improve patient outcomes. Concerns of toxicity have limited enthusiasm for the utilization of re-irradiation as a treatment option. However, using modern imaging technology and precision radiotherapy delivery techniques re-irradiation has proven a feasible option achieving both a palliative benefit and prolongation of survival with low toxicity rates. The evolution of re-irradiation as a treatment modality for recurrent grade 4 glioma is reviewed. In addition, potential targeted radiosensitizers to be used in conjunction with re-irradiation are also discussed.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Howard SP, Krauze A, Chan MD, et al. The evolving role for re-irradiation in the management of recurrent grade 4 glioma. J Neurooncol. 2017. PMID: 28386661. doi:10.1007/s11060-017-2392-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。